Allarity <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Landmark Phase 2 Results: Stenoparib Surpasses 25-Month Median Overall Survival in Advanced Ovarian Cancer Trial
Allarity Therapeutics Inc. has announced new and updated clinical data from its ongoing Phase 2 trial evaluating stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, in patients with advanced ovarian cancer. The results, which were presented at the American Association for Cancer Research (AACR) 7th Biennial Special Conference on Ovarian Cancer held September 19-21, 2025, in Denver, Colorado, show that median overall survival among platinum-resistant and refractory ovarian cancer patients receiving stenoparib/2X-121 twice daily has now surpassed 25 months. Clinical benefit was observed in patients with both BRCA wild-type and BRCA-mutated genetics. The company noted that two patients remain on therapy after more than 24 months, including one with primary platinum-refractory disease who remains alive more than two years after enrollment. The data are available via the scientific publications section of Allarity Therapeutics' website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-090872), on September 24, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。